Clinical trials: sargramostim
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00026312
- Testing
- Aldesleukin, Dinutuximab, Isotretinoin
- Where
- 197 sites in United States, Australia and 3 more
- Volunteers
- 1,449 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
High Risk Neuroblastoma
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
This phase III trial is studying the side effects of giving monoclonal antibody Ch14.18 together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in treating patients with neuroblastoma.
- Trial name
- NCT01041638
- Testing
- Aldesleukin, Diagnostic Laboratory Biomarker Analysis, Dinutuximab
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
High-Risk Neuroblastoma Chemotherapy Without G-CSF
Patients will be asked to participate in this study because patients have been diagnosed with high-risk neuroblastoma, a common childhood cancer which has aggressive features. If left untreated, high-risk neuroblastoma is fatal.
- Trial name
- SPRING (NCT02786719)
- Testing
- Topotecan, Cyclophosphamide, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Baylor College of Medicine
Neuroblastoma
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF).
- Trial name
- NCT03033303
- Testing
- Hu3F8, GM-CSF, Isotretinoin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
To determine the impact of maintenance therapy in patients with MDS/AML in remission.
- Trial name
- NCT01700673
- Testing
- Azacitidine, Sargramostim
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematologic Malignancies
G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
The purposes of this study are: To examine the engraftment rate in patients receiving in vivo T-cell-depleted G-CSF stimulated bone marrow from partially mismatched related donors.
- Trial name
- G-CSF PMRD (NCT00228813)
- Testing
- Granulocyte Colony Stimulating Factor
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Pediatric Sepsis-induced MODS
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
This study is an open-label, multi-center, interventional trial in which children with sepsis-induced MODS undergo surveillance immune function testing beginning on Day 2 of MODS.
- Trial name
- GRACE (NCT03769844)
- Testing
- GM-CSF
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Nationwide Children's Hospital
Leukemia
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the transplanted stem cells.
- Trial name
- NCT00049517
- Testing
- sargramostim, busulfan, cyclophosphamide
- Where
- 99 sites in United States, Israel
- Volunteers
- 657 people
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoma, Myeloma
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though the potential toxicities of the procedure remain high.
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia
- Trial name
- NCT00580034
- Testing
- Campath Purged Non-myeloablative ASCT, Donor Apheresis
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- David Rizzieri, MD
Neuroblastoma
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00072358
- Testing
- anti-GD2 murine IgG3 monoclonal antibody 3F8
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Lymphoma
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and…
- Conditions
- Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies
- Trial name
- NCT00801931
- Testing
- Alemtuzumab, Total Body Irradiation, Melphalan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Leukemia
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic…
- Trial name
- NCT00323557
- Testing
- Sargramostim (GM-CSF), Pneumococcal Vaccine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Peripheral Arterial Disease
Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)
The PROPEL study will test the hypothesis that GM-CSF combined with supervised treadmill exercise will significantly improve functional performance in patients with PAD more than GM-CSF alone or supervised treadmill exercise…
- Trial name
- PROPEL (NCT01408901)
- Testing
- Supervised Treadmill Exercise Therapy, Health education sessions (Control), granulocyte macrophage colony stimulating factor (GM-CSF)
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Northwestern University
Leukemia
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
The relapse of acute leukemia, MDS and blast phase CML after allogeneic transplantation affects approximately 1/3 to 1/2 of all transplant recipients and is the main cause of treatment failure.
- Trial name
- NCT00548847
- Testing
- GM-CSF, Interferon-α-2b
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emory University
Breast Cancer
Herceptin and GM-CSF for Metastatic Breast Cancer
Primary Objectives: 1. To determine the patient's tumor response rate that this protocol will produce. 2. To determine the 1 year progression-free survival that this protocol will produce. Secondary Objective: 1.
- Trial name
- NCT00429104
- Testing
- Herceptin, GM-CSF
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and rituximab, with sargramostim (GM-CSF) can help to control previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT00381004
- Testing
- Cyclophosphamide, Fludarabine, Sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in childhood, with nearly 50% of patients presenting with widespread metastatic disease.
- Trial name
- NCT01857934
- Testing
- cyclophosphamide, topotecan, hu14.18K322A
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- St. Jude Children's Research Hospital
Malignant Glioma, High Grade Glioma
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of…
- Trial name
- ACTION (NCT03334305)
- Testing
- TTRNA-DC vaccines with GM-CSF, Dose-intensified TMZ, Autologous Hematopoietic Stem cells (HSCs)
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Florida